blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP1732548

EP1732548 - METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS [Right-click to bookmark this link]
StatusPatent maintained as amended
Status updated on  28.07.2023
Database last updated on 28.03.2024
Most recent event   Tooltip28.07.2023Patent maintained (B2 publication)published on 30.08.2023  [2023/35]
Applicant(s)For all designated states
Acorda Therapeutics, Inc.
420 Saw Mill River Road
Ardsley, NY 10502 / US
[2013/11]
Former [2006/51]For all designated states
Acorda Therapeutics, Inc.
15 Skyline Drive
Hawthorne NY 10531 / US
Inventor(s)01 / BLIGHT, Andrew, R.
10 Oskar Drive
Mahopac, NY 10541 / US
02 / MARINUCCI, Lawrence
25 Bank Street
Apartment 214H
White Plains, NY 10606 / US
03 / COHEN, Ron
246 Harriman Road
Irvington, NY 10533 / US
 [2023/35]
Former [2006/51]01 / BLIGHT, Andrew, R.
10 Oskar Drive
Mahopac, NY 10541 / US
02 / MARINUCCI, Lawrence
25 Bank Street Apartment 214H
White Plains, NY 10606 / US
03 / COHEN, Ron
246 Harriman Road
Irvington, NY 10533 / US
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[2023/35]
Former [2012/19]Goodfellow, Hugh Robin, et al
Carpmaels & Ransford One Southampton Row
London WC1B 5HA / GB
Former [2009/48]Ouzman, Beverley Nicola Claire, et al
Murgitroyd & Company Scotland House 165-169 Scotland Street
Glasgow G5 8PL / GB
Former [2006/51]Ouzman, Beverley Nicola Claire, et al
Murgitroyd and Company, 165-169 Scotland Street
Glasgow G5 8PL / GB
Application number, filing date05732613.411.04.2005
[2006/51]
WO2005US12427
Priority number, dateUS20040560894P09.04.2004         Original published format: US 560894 P
US2005010255908.04.2005         Original published format: US 102559
[2006/51]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2005099701
Date:27.10.2005
Language:EN
[2005/43]
Type: A2 Application without search report 
No.:EP1732548
Date:20.12.2006
Language:EN
The application published by WIPO in one of the EPO official languages on 27.10.2005 takes the place of the publication of the European patent application.
[2006/51]
Type: B1 Patent specification 
No.:EP1732548
Date:08.06.2011
Language:EN
[2011/23]
Type: B9 Corrected patent specification 
No.:EP1732548
Date:21.03.2012
[2012/12]
Type: B2 New European patent specification 
No.:EP1732548
Date:30.08.2023
Language:EN
[2023/35]
Search report(s)International search report - published on:US23.03.2006
(Supplementary) European search report - dispatched on:EP07.05.2009
ClassificationIPC:A61K31/44
[2006/51]
CPC:
A61K31/4409 (EP,US); A61K31/435 (EP,US); A61K31/44 (EP,US);
A61K9/20 (US); A61P17/02 (EP); A61P19/08 (EP);
A61P21/00 (EP); A61P25/00 (EP); A61P25/28 (EP);
A61P43/00 (EP) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2023/35]
Former [2006/51]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  MC,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
Extension statesAL09.10.2006
BA09.10.2006
HR09.10.2006
LV09.10.2006
MK09.10.2006
YU09.10.2006
TitleGerman:VERFAHREN ZUR VERWENDUNG VON AMINOPYRIN-ZUSAMMENSETZUNGEN MIT VERZÖGERTER FREISETZUNG[2010/45]
English:METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS[2006/51]
French:UTILISATION DE COMPOSITIONS D'AMINOPYRIDINE A LIBERATION SOUTENUE[2006/51]
Former [2006/51]VERFAHREN ZUR VERWENDUNG VON AMINOPYRIN-ZUSAMMENSETZUNG MIT VERZÖGERTER FREISETZUNG
Entry into regional phase09.10.2006National basic fee paid 
09.10.2006Search fee paid 
09.10.2006Designation fee(s) paid 
09.10.2006Examination fee paid 
Examination procedure09.10.2006Amendment by applicant (claims and/or description)
09.10.2006Examination requested  [2006/51]
27.08.2009Despatch of a communication from the examining division (Time limit: M04)
16.10.2009Reply to a communication from the examining division
26.10.2009Despatch of a communication from the examining division (Time limit: M04)
05.03.2010Reply to a communication from the examining division
30.03.2010Despatch of a communication from the examining division (Time limit: M02)
12.04.2010Reply to a communication from the examining division
12.11.2010Communication of intention to grant the patent
17.03.2011Fee for grant paid
17.03.2011Fee for publishing/printing paid
Divisional application(s)EP11160247.0  / EP2377536
EP11168901.4  / EP2422782
EP11179067.1  / EP2460521
EP21170762.5  / EP3922248
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  27.08.2009
Opposition(s)Opponent(s)01  07.03.2012  14.03.2012  ADMISSIBLE
Synthon B.V.
Microweg 22
6545 CM Nijmegen / NL
Opponent's representative
Benneker, Franciscus B. G., et al, et al
Synthon BV
Microweg 22
6545 CM Nijmegen / NL
 02  08.03.2012  23.03.2012  ADMISSIBLE
neuraxpharm Arzneimittel GmbH
Elisabeth-Selbert-Str. 23
40764 Langenfeld / DE
Opponent's representative
Königer, Karsten, et al, et al
Harmsen Utescher
Rechtsanwalts- und Patentanwaltspartnerschaft mbB
Neuer Wall 80
20354 Hamburg / DE
 [2023/27]
Former [2013/22]
Opponent(s)01  07.03.2012  14.03.2012  ADMISSIBLE
Synthon B.V.
Microweg 22
6545 CM Nijmegen / NL
Opponent's representative
Prins, Hendrik Willem, et al, et al
Arnold & Siedsma Sweelinckplein 1
2517 GK The Hague / NL
 02  08.03.2012  23.03.2012  ADMISSIBLE
neuraxpharm Arzneimittel GmbH
Elisabeth-Selbert-Str. 23
40764 Langenfeld / DE
Opponent's representative
Königer, Karsten, et al, et al
Harmsen Utescher
Rechtsanwälte Patentanwälte
Neuer Wall 80
D-20354 Hamburg / DE
Former [2012/16]
Opponent(s)01  07.03.2012  14.03.2012  ADMISSIBLE
Synthon B.V.
Microweg 22
6545 CM Nijmegen / NL
Opponent's representative
Prins, Hendrik Willem, et al, et al
Arnold & Siedsma Sweelinckplein 1
2517 GK The Hague / NL
 02  08.03.2012    ADMISSIBLE
neuraxpharm Arzneimittel GmbH & Co. KG
Elisabeth-Selbert-Strasse 23
40764 Langenfeld / DE
Opponent's representative
Königer, Karsten
Harmsen Utescher
Rechtsanwälte Patentanwälte
Neuer Wall 80
D-20354 Hamburg / DE
Former [2012/15]
Opponent(s)01  07.03.2012    ADMISSIBLE
Synthon B.V.
Microweg 22
6545 CM Nijmegen / NL
Opponent's representative
Prins, Hendrik Willem
Arnold & Siedsma Sweelinckplein 1
2517 GK The Hague / NL
16.04.2012Invitation to proprietor to file observations on the notice of opposition
02.01.2013Reply of patent proprietor to notice(s) of opposition
11.11.2013Date of oral proceedings
19.12.2013Despatch of minutes of oral proceedings
09.03.2021Despatch of a communication from the opposition division (Time limit: M02)
16.03.2021Reply to a communication from the opposition division
22.11.2021Despatch of a communication from the opposition division (Time limit: M02)
01.02.2022Reply to a communication from the opposition division
14.04.2022Despatch of a communication from the opposition division (Time limit: M02)
20.06.2022Reply to a communication from the opposition division
02.08.2022Despatch of a communication from the opposition division (Time limit: M02)
08.02.2023Despatch of interlocutory decision in opposition
18.02.2023Legal effect of interlocutory decision in opposition
06.06.2023Despatch of communication that the patent will be maintained as amended
26.07.2023Fee for printing new specification paid
Appeal following opposition27.02.2014Appeal received No.  T0421/14
29.04.2014Statement of grounds filed
03.09.2019Result of appeal procedure: maintenance in amended form
17.02.2014Appeal received No.  T0421/14
28.04.2014Statement of grounds filed
03.09.2019Result of appeal procedure: maintenance in amended form
02.09.2019Date of oral proceedings
11.09.2019Minutes of the oral proceedings despatched
Fees paidRenewal fee
27.04.2007Renewal fee patent year 03
25.04.2008Renewal fee patent year 04
29.04.2009Renewal fee patent year 05
26.04.2010Renewal fee patent year 06
25.04.2011Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X]IE82916  (ELAN CORP PLC) [X] 1-19* claim 1 *;
 [X]  - BEVER C T, "THE CURRENT STATUS OF STUDIES OF AMINOPYRIDINES IN PATIENTS WITH MULTIPLE SCLEROSIS", ANNALS OF NEUROLOGY, BOSTON, US, (19940101), vol. 36, ISSN 0364-5134, pages S118 - S121, XP000653261 [X] 1-19 * table 1 *

DOI:   http://dx.doi.org/10.1002/ana.410360728
 [X]  - BEVER C T JR ET AL, "The effects of 4-aminopyridine in multiple sclerosis patients: Results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial", NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, US, (19940601), vol. 44, no. 6, ISSN 0028-3878, pages 1054 - 1059, XP009115521 [X] 1-19 * see "Treatment" *
 [X]  - SCHWID S R ET AL, "Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis", NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, US, (19970401), vol. 48, no. 4, ISSN 0028-3878, pages 817 - 821, XP009115522 [X] 1-19 * see "Procedure". *
 [X]  - VAN DIEMEN H A M ET AL, "THE EFFECT OF 4 AMINOPYRIDINE ON CLINICAL SIGNS IN MULTIPLE SCLEROSIS A RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND CROSS-OVER STUDY", ANNALS OF NEUROLOGY, (1992), vol. 32, no. 2, ISSN 0364-5134, pages 123 - 130, XP002524401 [X] 1-19 * abstract *

DOI:   http://dx.doi.org/10.1002/ana.410320203
International search[X]EP0484186  (ELAN CORP PLC [IE]);
 [X]  - FUJIHARA ET AL, "The effects of 4-aminopyridine on motor evoked potentials in multiple sclerosis.", JOURNAL OF THE NEUROLOGICAL SCIENCES., (1988), vol. 159, pages 102 - 106, XP001151991

DOI:   http://dx.doi.org/10.1016/S0022-510X(98)00143-9
otherUS8007826
 EP2377536
 US8663685
    - GOODMAN ANDREW D ET AL, "Placebo-controlled double-blinded dose ranging study of fampridine-SR in multiple sclerosis", NEUROLOGY, vol. 60, no. 5 Supp, (20030311), XP009154279
    - "Final Program, Abstract Listing and Meeting Information", ACTRIMS-ECTRIMS 2002, (20020918), XP055502446
    - Goodman A. D. ET AL, "P 308: PLACEBO-CONTROLLED DOUBLE-BLINDED DOSE RANGING STUDY OF FAMPRIDINE-SR IN MULTIPLE SCLEROSIS", Multiple Sclerosis, (20020000), pages S116 - S117, XP055502452
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.